Millie
your market intelligence analyst
Search Results
Edit Save
1,153 results
SynBioBeta 09/17/2020 09:04
Inaugural report reveals fermentation as the next pillar of alternative proteins, enabling a new wave of innovative products and accelerating the industry WASHINGTON – A first-of-its kind report released today by The Good Food Institute (GFI) reveals that globally, 2019 and the first seven months of 2020 were record periods of investment in fermentation companies [...]. .
SynBioBeta 09/17/2020 07:41
Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and commercial milestones and royalty payments September 16, 2020 04:30 PM Eastern Daylight Time CAMBRIDGE & BOSTON, [...]. .
SynBioBeta 09/16/2020 09:58
Debut Bio’s biosynthesis platform provides a scalable biomanufacturing approach while eliminating the need for traditional precious metal catalysts and toxic reagents SAN DIEGO (PRWEB) SEPTEMBER 15, 2020 Debut Biotechnology, a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Lab’s Biotechnology Grand Challenge.
SynBioBeta 09/15/2020 09:36
EMERYVILLE, Calif., Sept. 15, 2020 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that its Reb M natural sweetener has received approval for use in food by Health Canada, the government department that is [...]. .
SynBioBeta 09/15/2020 09:34
September 15, 2020 Nonprofit Will Enable Access to Proprietary SHERLOCK™ CRISPR-based Technology to Support Third-party Development of COVID-19 Diagnostic Tests Proceeds to Support Racial and Gender Diversity in STEM Cambridge, Mass., September 15, 2020 – Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced the formation of [...]. .
SynBioBeta 09/13/2020 13:21
What is the future of food? Looking at what’s on shelves and in freezers during a quick trip to the local grocery store, it’s easy to see that we are quickly moving towards a future of plant-based foods. While they provide consumers more environmentally friendly food choices, many still have questions about the nutritional merits […]. .
SynBioBeta 09/09/2020 06:09
One of the largest deep tech investments of 2020 to fuel additional product releases and development of breakthrough materials EMERYVILLE, Calif., Sept. 8, 2020 /PRNewswire/ — Science and material innovation company Zymergen today announced $300M in new investment to accelerate its delivery of revolutionary, high performance materials.
SynBioBeta 09/06/2020 02:47
When Covid hit and hospitals started reporting shortages of hydroxychloroquine and other medicines vital to patients with conditions like malaria, lupus, asthma, and COPD, it became clear that our drug supply chain was broken. Nearly all plant-based medicines — including hydroxychloroquine — are made outside the US because the medicinal plants used to make them […]. .
SynBioBeta 09/03/2020 11:10
Biotechnology company focused on using fermentation to produce cannabinoids for safe, legal, and effective consumer products and pharmaceuticals scales to 15,000-liter production runs of CBG BERKELEY, Calif., Sept. 3, 2020 /PRNewswire/ — Demetrix Inc., a biotechnology company that makes safe and effective cannabinoids, today announced that it has commenced 15,000-liter demo-scale fermentation production of the rare cannabinoid [...]. .
SynBioBeta 09/03/2020 07:32
— Data compiled in collaboration with Saint Louis University and independently verified by Colorado State University — September 02, 2020 08:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (Nasdaq: TWST) today announced data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies, both Immunoglobulin G (IgG) antibodies and substantially smaller [...]. .
SynBioBeta 09/02/2020 11:06
First demonstration of tropane alkaloids, plant molecules used to treat neuromuscular disorders, produced in yeast Published in the journal Nature and led by Antheia co-founder and CEO and Stanford Professor Dr. Christina Smolke MENLO PARK, Calif., Sept. 2, 2020 /PRNewswire/ — A new paper published today in the journal Nature describes the first successful microbial biosynthesis of the tropane alkaloids [...]. .
SynBioBeta 09/01/2020 06:01
SINGAPORE, Sept. 1, 2020 /PRNewswire/ — GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK) entered an exclusive partnership with Philippines biotech company, IP Biotech. ). This will allow the firm to distribute a breakthrough test kit designed to measure the levels of neutralizing antibodies in recovered COVID-19 patients. The newly-developed cPass™ SARS CoV-2 Neutralization Antibody Detection Kit is an essential component […]. .
SynBioBeta 09/01/2020 05:58
Twist Bioscience manufactures DNA. In the world of synthetic biology—a booming field that seeks to grow, harvest, and ferment new sustainable goods—custom DNA is a key ingredient. Before the pandemic hit, Twist saw its stock price nearly triple since its IPO in 2018. How is this pillar of the booming synthetic biology industry weathering the Covid-19 crisis? […]. .
SynBioBeta 08/30/2020 01:37
By zeroing in on a notorious class of enzymes associated with cancer, Reverie Labs puts the power of cloud computing to its full potential Can two smart, motivated college grads start a pharmaceutical company in an apartment with a few laptops? Just ask Jonah Kallenbach and Ankit Gupta, co-founders of Reverie Labs. Based in Cambridge, Reverie Labs is applying […]. .
SynBioBeta 08/28/2020 09:07
WOBURN, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications